Orthobiologics for Knee Arthritis: PRP, GFC, ACS and BMAC — What the Evidence Supports

Quick answer: Orthobiologics are treatments prepared from a patient’s own blood, bone marrow or other biological sources and used with the aim of influencing pain, inflammation and joint biology. For knee osteoarthritis, the evidence is not equal across treatments. PRP currently has the strongest clinical consensus support for selected patients with mild-to-moderate disease. GFC is promising but has a smaller clinical evidence base. Autologous conditioned serum (ACS) has mixed trial evidence. Bone-marrow-derived and other cell-based therapies are more invasive, more heterogeneous and need particularly careful counselling. None of these treatments should be sold as guaranteed cartilage regrowth or a cure for advanced arthritis.

What “regenerative therapy” should mean in knee arthritis

The term regenerative medicine is used very loosely. In clinical orthopaedics, it is more useful to talk about orthobiologics: biological preparations used to modify the joint environment or support tissue response. The important question is not whether a treatment carries a regenerative label. It is whether there is credible evidence for a specific preparation, a specific stage of osteoarthritis and a realistic clinical goal.

For most patients, that goal is symptom control and better function while preserving activity. Structural regeneration is a much higher bar. Improvement in pain scores after an injection does not automatically mean cartilage has regrown, the arthritis has reversed or a future knee replacement has been prevented.

Start with diagnosis and disease stage—not the injection name

Before considering an orthobiologic, the diagnosis should be clear. Knee pain can arise from osteoarthritis, patellofemoral overload, inflammatory disease, referred pain, insufficiency injury and several other causes. Weight-bearing X-rays, examination, symptoms, alignment and functional limitation often matter more than simply choosing between PRP, GFC, ACS or BMAC.

Exercise therapy, weight management where relevant, strength restoration, activity modification and appropriate analgesic strategies remain foundational. An injection is usually an adjunct to a broader treatment plan, not a replacement for it.

PRP: currently the best-supported injectable orthobiologic

Platelet-rich plasma (PRP) is prepared from autologous blood and concentrates platelets to varying degrees. PRP is not a single standardized product: platelet concentration, leukocyte content, activation, number of injections and preparation method can differ substantially.

The 2024 ESSKA-ORBIT consensus concluded that there is sufficient preclinical and clinical evidence to support PRP in knee osteoarthritis, with the strongest evidence in mild-to-moderate disease, particularly Kellgren-Lawrence grades 1–3. A separate ESSKA-ICRS appropriateness consensus also found PRP most appropriate after conservative treatment has not provided adequate relief, while uncertainty is much greater in KL grade 4 disease.

This makes PRP a reasonable evidence-based option for selected patients, but not a universal first treatment and not a guarantee of structural regeneration.

GFC: promising, but with a narrower evidence base than PRP

Growth Factor Concentrate (GFC) is another autologous blood-derived preparation designed to concentrate platelet-derived growth factors while reducing some cellular components. It is sometimes described as an “advanced PRP”, but that phrase can be misleading because preparation systems and evidence are not interchangeable.

A 2024 systematic review of GFC for knee osteoarthritis identified only three eligible clinical studies. The authors concluded that GFC appeared safe and potentially effective, particularly in mild-to-moderate disease, but specifically called for adequately powered multicentre randomized trials and direct comparisons with other orthobiologics before routine use can be defined with greater confidence.

For a detailed explanation of preparation and evidence, see GFC Injection Full Form: Growth Factor Concentrate Explained. For patient selection, see GFC Injection for Knee Arthritis: Who May Benefit and Who May Not.

Patients considering GFC should also understand expected reactions and aftercare. See GFC Injection Side Effects: Pain, Swelling and Red Flags.

ACS: biologically interesting, but clinical evidence is conflicting

Autologous conditioned serum (ACS) is produced by incubating a patient’s blood under controlled conditions to increase anti-inflammatory mediators, including interleukin-1 receptor antagonist, before serum is separated and injected.

ACS is biologically attractive because osteoarthritis includes inflammatory signalling as well as mechanical degeneration. However, the clinical evidence is not settled. A 2024 meta-analysis of randomized trials found improvement when ACS was pooled against several comparators, but when the analysis was restricted to saline placebo there was no statistically significant advantage at six months. The authors concluded that higher-quality multicentre randomized trials are needed.

So ACS should be discussed as a potentially useful but less established option—not as a proven disease-modifying treatment.

BMAC and cell-based therapies: a different level of complexity

Bone marrow aspirate concentrate (BMAC) is obtained by aspirating bone marrow, commonly from the iliac crest, and concentrating a mixture that can contain platelets, cytokines and nucleated cells. Calling BMAC simply a “stem cell injection” is scientifically imprecise. The number and characteristics of progenitor cells vary, and BMAC is not equivalent to an expanded stem-cell product manufactured in a laboratory.

Recent ESSKA consensus work on cell-based therapy emphasizes that these treatments are more invasive and technically complex than blood-derived orthobiologics. Evidence is heterogeneous across cell sources, processing methods, doses and patient groups. A 2026 ESSKA-ICRS consensus further evaluated appropriateness by age, osteoarthritis grade, joint compartment, BMI and cell source—illustrating why cell-based therapy should not be treated as a one-size-fits-all injection.

For a patient, the practical implication is simple: if a clinic advertises a “stem cell cure” without specifying what biological product is being used, the evidence for that exact product, the regulatory status and realistic outcomes, caution is warranted.

Which treatment is “best”: PRP, GFC, ACS or BMAC?

There is no single best orthobiologic for every knee. The evidence is currently strongest and most standardized around PRP for selected mild-to-moderate osteoarthritis. GFC is promising but supported by fewer comparative studies. ACS has plausible anti-inflammatory biology but conflicting randomized evidence. BMAC and other cell-based approaches remain more heterogeneous and should generally be considered only after careful assessment of why a more invasive biological treatment is being proposed.

The choice should therefore be based on the diagnosis, arthritis grade, alignment, inflammatory activity, previous treatment, age, activity goals, medical risk, cost-benefit discussion and the quality of evidence for the exact preparation—not on marketing terminology.

Who is more likely to be considered for an orthobiologic?

The strongest overall rationale is usually in symptomatic early-to-moderate osteoarthritis when exercise-based care and other appropriate conservative measures have not provided sufficient relief, the joint is not dominated by severe fixed deformity, and the patient understands that the goal is symptom and function improvement rather than guaranteed cartilage regeneration.

Age alone is not the only determinant. Radiographic grade, compartment involvement, effusion, body mass, alignment, activity level and the source of pain can all affect decision-making. The same injection may make sense in one KL grade 2 knee and make little sense in another patient with severe deformity and bone-on-bone disease.

When regenerative injections are unlikely to solve the main problem

Advanced osteoarthritis with severe joint-space loss, fixed deformity, major instability, persistent night pain or substantial loss of function may represent a mechanical and structural problem that cannot reasonably be expected to reverse with an injection. Orthobiologics can sometimes still be discussed for temporary symptom management in selected patients who are not ready or able to undergo surgery, but expectations must be different.

When advanced disease requires surgical discussion, the question changes from “which injection?” to “what operation, what timing and what recovery plan?” For a separate evidence review, read Robotic Knee Replacement in 2026: What the Evidence Supports and What It Does Not.

Can orthobiologics regrow cartilage?

This is where patient communication must be particularly precise. Laboratory studies can demonstrate biological effects on inflammatory pathways, cell signalling or tissue behaviour. Some imaging and biomarker studies are also encouraging. But a clinical claim that an injection reliably regrows normal articular cartilage, reverses established osteoarthritis or eliminates the future need for replacement surgery requires much stronger evidence than is currently available for routine knee OA care.

A responsible interpretation is that some orthobiologics can improve pain and function in appropriately selected patients, with different degrees of evidence. That is clinically meaningful even without claiming a cure.

A note on cell-based therapy and regulation in India

Regenerative medicine is also a regulatory issue, not only a scientific one. In August 2026, the Government of India stated that the Ministry of Health and Family Welfare’s Centre for Evidence Based Guidelines had issued 2025–2026 evidence-based guidelines on stem-cell therapy across disease indications. Patients considering any product marketed as a stem-cell or cell-based treatment should ask what exactly is being administered, whether it is a point-of-care concentrate or an expanded/manufactured cell product, what evidence supports that use, and what regulatory framework applies.

This distinction is important because PRP, GFC, ACS, BMAC and expanded cell products are not interchangeable therapies simply because they are all marketed under the broad word “regenerative.”

A practical evidence-based framework

1. Confirm the diagnosis. Do not treat an MRI report or an X-ray grade in isolation.

2. Stage the arthritis and identify mechanical factors. Alignment, instability, compartment involvement and deformity affect treatment choice.

3. Optimize the foundations. Exercise, strength, weight management and activity modification remain central.

4. Match the orthobiologic to the evidence. PRP currently has the strongest consensus support; GFC, ACS and cell-based therapies require increasingly nuanced discussion.

5. Define the goal before treatment. Pain reduction and functional improvement are realistic endpoints; guaranteed regeneration is not.

6. Reassess if symptoms persist. A failed injection may mean the diagnosis, disease stage or treatment goal needs reconsideration—not simply that another brand of biologic is required.

Frequently asked questions

Is PRP the same as GFC?

No. Both are autologous blood-derived orthobiologics, but their preparation and final composition differ. The evidence base for PRP is considerably larger, while GFC-specific clinical research is still developing.

Is BMAC a stem-cell cure for knee arthritis?

No. BMAC is a heterogeneous bone-marrow-derived concentrate and should not be equated with a purified or expanded stem-cell product. Current evidence does not justify describing it as a cure for osteoarthritis.

Can I take an orthobiologic instead of knee replacement?

That depends on why replacement is being considered. In early-to-moderate disease, orthobiologics may be one part of non-operative care. In advanced structural disease with major deformity and disability, an injection should not be presented as biologically equivalent to correcting the mechanical problem with arthroplasty.

Which patients should avoid chasing repeated injections?

Patients with severe fixed deformity, rapidly progressive symptoms, suspected infection or inflammatory disease, major instability, fracture/insufficiency injury, or a diagnosis that has not been established need reassessment rather than repeated injections.

Does improvement after an injection prove cartilage regeneration?

No. Pain and function can improve through anti-inflammatory and biological mechanisms without demonstrating restoration of normal articular cartilage.

Selected evidence and guidance

ESSKA-ORBIT consensus on PRP for knee osteoarthritis (2024) — supports PRP as a valid option, mainly in KL grades 1–3.

ESSKA-ICRS PRP appropriateness consensus (2024) — patient-focused recommendations across OA grades and clinical scenarios.

Systematic review of GFC for knee osteoarthritis (2024) — promising results but only three eligible clinical studies and a need for larger multicentre trials.

ACS randomized-trial meta-analysis (2024) — conflicting results and insufficient data for firm conclusions.

ESSKA-ORBIT consensus on cell-based therapy (2025) — formal guidance on indications, preparation and administration of cell-based orthobiologics.

ESSKA-ICRS cell-based therapy appropriateness consensus (2026) — evaluates clinical scenarios by cell source, age, OA grade, compartment and BMI.

Government of India update on regenerative-medicine guidance (11 August 2026) — notes 2025–2026 evidence-based stem-cell therapy guidelines issued through the Ministry of Health and Family Welfare framework.

About the author

Dr. Mayur Rabhadiya is an Orthopedic & Robotic Joint Replacement Surgeon in Ghatkopar, Mumbai, with a clinical focus on knee arthritis, evidence-based non-surgical treatment, orthobiologics, minimally invasive mini-subvastus robotic knee replacement and hip replacement. This article is for general education and does not replace an individualized clinical assessment.